AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The Company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Type
Public
HQ
North Chicago, US
Founded
2013
Size (employees)
29,000 (est)
Website
abbvie.com
AbbVie was founded in 2013 and is headquartered in North Chicago, US
Report incorrect company information

Key People/Management at AbbVie

Richard Gonzalez

Richard Gonzalez

Chairman of the Board and Chief Executive Officer
Carlos Alban

Carlos Alban

Executive Vice President, Commercial Operations
Timothy Richmond

Timothy Richmond

Senior Vice President, Human Resources​
Azita Saleki-Gerhardt

Azita Saleki-Gerhardt

Senior Vice President, Operations
Karen Hale

Karen Hale

Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke

Wulff-Erik von Borcke

President, Pharmacyclics
Show more

AbbVie Office Locations

AbbVie has offices in Singapore, Campoverde, Sligo, San Francisco and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Show all (16)
Report incorrect company information

AbbVie Financials and Metrics

AbbVie Financials

AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
USD

Revenue (Q1, 2018)

7.9 b

Gross profit (Q1, 2018)

6 b

Gross profit margin (Q1, 2018), %

75.7%

Net income (Q1, 2018)

2.8 b

EBIT (Q1, 2018)

2.9 b

Market capitalization (21-May-2018)

168.6 b

Closing share price (21-May-2018)

106.2

Cash (31-Mar-2018)

9 b

EV

159.9 b
AbbVie's current market capitalization is $168.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.8 b20 b22.9 b25.6 b

Revenue growth, %

6%15%12%

Cost of goods sold

4.6 b4.4 b4.5 b5.8 b

Gross profit

14.2 b15.5 b18.4 b19.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

4.7 b4.6 b4.9 b5 b5 b5.5 b5.9 b6 b6.5 b6.4 b6.54 t6.9 b7.9 b

Cost of goods sold

1.1 b1.1 b1.1 b1.1 b942 m916 m1.2 b1.4 b1.4 b1.5 b1.62 t1.5 b1.9 b

Gross profit

3.6 b3.5 b3.8 b3.9 b4.1 b4.6 b4.8 b4.6 b5 b4.9 b4.92 t5.4 b6 b

Gross profit Margin, %

77%76%77%78%81%83%80%77%78%77%75%78%76%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6 b8.3 b8.4 b5.1 b

Accounts Receivable

3.9 b3.7 b4.7 b4.8 b

Inventories

1.2 b1.1 b1.7 b1.4 b

Current Assets

17.8 b16.1 b16.3 b16.2 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

9 b8.1 b9.1 b7.7 b7.9 b7.4 b9.2 b7.6 b6.3 b6.2 b4.7 b6.1 b9 b

Accounts Receivable

3.8 b3.7 b3.7 b3.6 b4.2 b4.4 b4.6 b4.8 b5 b5 b4.7 b4.9 b5.8 b

Inventories

1.2 b1.1 b1 b1 b1 b1.6 b1.8 b1.8 b1.8 b1.6 b1.4 b1.6 b1.7 b

Current Assets

16.5 b17.3 b17.8 b17.6 b15.4 b16.9 b17.9 b16.6 b16.8 b16.3 b15.5 b17 b20.4 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1 b1.8 b5.1 b6 b

Inventories

(56 m)(203 m)(434 m)(38 m)

Accounts Payable

(426 m)(193 m)1.5 b(1.2 b)

Cash From Operating Activities

6.3 b3.5 b7.5 b7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

964 m980 m1.1 b2.6 b1 b2.4 b3.6 b1.4 b3 b4.6 b1.7 b3.6 b2.8 b

Depreciation and Amortization

593 m158 m348 m575 m268 m557 m861 m374 m753 m445 m

Inventories

20 m(75 m)(160 m)(446 m)19 m(160 m)28 m71 m1 m(71 m)

Accounts Payable

(1 m)188 m409 m1.3 b42 m89 m(975 m)(266 m)(530 m)191 m
USDY, 2018

EV/EBIT

55.1 x

Revenue/Employee

273.6 k

Financial Leverage

19.5 x
Show all financial metrics

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRx (156)April 28, 2016$5.80 b
Report incorrect company information

AbbVie News and Updates

AbbVie bows to pressure to keep cheaper Imbruvica formula on the market

When AbbVie rolled out a single-tablet formulation of its blood cancer drug Imbruvica earlier this year, it pitched the pill to doctors and patients as a convenience. But that convenience came with a hefty price tag—the cost of the smallest dose tripled in price—and that didn't go over well.

Hormone Refractory Prostate Cancer Market Significant Profits Estimated to be Generated by 2024

North America will continue to dominate the global Hormone Refractory Prostate Cancer market for due to high prevalence which are diagnosed with advanced technology. Posted via Industry Today. Follow us on Twitter @IndustryToday

New Research Report on Retinal Drugs And Biologics Market, 2017-2027

Future Market Insights has announced the addition of the “Retinal Drugs And Biologics Market: Global Industry Analysis and Opportunity Assessment, 2017-2027"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday

With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out

Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hep C sales cratered in the first quarter—falling even more than expected—its CFO admitted that the company's bottoming out. The good news? A trough implies growth ahe…
Show more
Report incorrect company information